0001209191-22-045296.txt : 20220810 0001209191-22-045296.hdr.sgml : 20220810 20220810181351 ACCESSION NUMBER: 0001209191-22-045296 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220808 FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ostertag Eric CENTRAL INDEX KEY: 0001765987 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 221153059 MAIL ADDRESS: STREET 1: C/O POSEIDA THERAPEUTICS, INC. STREET 2: 4242 CAMPUS POINT COURT, SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-08 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001765987 Ostertag Eric C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 1 1 1 0 Executive Chairman Common Stock 2022-08-08 4 P 0 142857 3.50 A 838824 D Common Stock 3659503 I See footnote Common Stock 3358455 I See footnote Common Stock 580292 I See footnote Common Stock 961445 I See footnote This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with sales effected on August 3, 2022 pursuant to a Rule 10b5-1 trading plan established independently of the reporting person by Transposagen Biopharmaceuticals and in connection with a planned dissolution of Transposagen Biopharmaceuticals. The reporting person will disgorge the full amount of any recoverable profits to the Issuer. The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee. The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person. The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee. /s/ Harry J. Leonhardt, Attorney-in-Fact 2022-08-10